Her2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype

International Journal of Surgical Pathology

Volumn 21, Issue 3, 2013, Pages 240-246

  Cruz Reyes, Carolina ^a   Gamboa Dominguez, Armando ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

amplification; gastric cancer; HER2; intestinal phenotype; Mexico; prevalence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; ENDOSCOPIC BIOPSY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

AMPLIFICATION; GASTRIC CANCER; HER2; INTESTINAL PHENOTYPE; MEXICO; PREVALENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84878236514     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896913481055     Document Type: Article

References (18)

1. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010 ; 78: 26-33
2. Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. Onco Targets Ther. 2011 ; 4: 21-28
3. Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008 ; 8: 363-374
4. Jørgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist. 2007 ; 12: 397-405
5. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010 ; 146: 264-275
6. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. J Hematol Oncol. 2010 ; 3: 11
7. Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?. Hum Pathol. 2012 ; 43: 413-422
8. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010 ; 376: 687-697
9. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer - guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010 ; 457: 299-307
10. Choritz H, Büsche G, Kreipe H. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch. 2011 ; 459: 283-289
11. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008 ; 52: 797-805
12. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007 ; 131: 18-43
13. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009 ; 40: 769-777
14. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: rare, heterogeneous an of no prognostic value. Conclusions from 924 cases of two independent series. Cell Oncol. 2010 ; 32: 57-65
15. Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol. 2012 ; 46: 31-37
16. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol. 2009 ; 135: 1331-1339
17. Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol. 2011 ; 34: 89-95
18. Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011 ; 17: 1501-1506